Glycogenic hepatopathy associated with hepatic steatosis in type 1 diabetes.

Autor: Teasdale S; Queensland Diabetes and Endocrine Centre, Mater Hospital Brisbane, Queensland, Australia. Electronic address: stephanie.teasdale@mater.org.au., Dong X; Translational Research Institute, Australia. Electronic address: xin.dong@tri.edu.au., Griffin A; QIMR Berghofer Medical Research Institute, Queensland, Australia. Electronic address: Alison.Griffin@health.qld.gov.au., Clark PJ; Gastroenterology unit, Mater Hospital Brisbane, Australia. Electronic address: paul.j.clark@uq.edu.au., Nisbet J; Queensland Diabetes and Endocrine Centre, Mater Hospital Brisbane, Queensland, Australia. Electronic address: Janelle.nisbet@mater.org.au., Morton A; Queensland Diabetes and Endocrine Centre, Mater Hospital Brisbane, Queensland, Australia. Electronic address: adam.morton@mater.org.au., Phillips L; Queensland Diabetes and Endocrine Centre, Mater Hospital Brisbane, Queensland, Australia. Electronic address: liza.phillips@mater.org.au., Sullivan MA; Mater Research Institute - The University of Queensland, TRI, Brisbane, Queensland, Australia. Electronic address: mitchell.sullivan@mater.uq.edu.au., Galloway G; Translational Research Institute, Australia. Electronic address: graham.galloway@tri.edu.au.
Jazyk: angličtina
Zdroj: Journal of diabetes and its complications [J Diabetes Complications] 2024 Nov; Vol. 38 (11), pp. 108870. Date of Electronic Publication: 2024 Sep 17.
DOI: 10.1016/j.jdiacomp.2024.108870
Abstrakt: Aims: Glycogenic hepatopathy is associated with significant psychosocial consequences and health costs. Metabolic Dysfunction-Associated Steatotic Liver Disease and glycogenic hepatopathy are frequently confused as "fatty liver" when seen on ultrasonography. We wished to examine liver fat and glycogen content in groups defined based on metabolic and liver disease phenotypes.
Methods: This case-control study undertaken in a tertiary hospital used nuclear proton magnetic resonance spectroscopy ( 1 H-MRS) to examine liver fat and glycogen content in five clinical groups, each containing five participants: 1. type 1 diabetes with glycogenic hepatopathy, 2. satisfactorily controlled type 1 diabetes with no liver disease, 3. poorly controlled type 1 diabetes without liver disease, 4. a control group of body mass index- and age-matched individuals without diabetes or liver disease, and 5. hepatic steatosis.
Results: Fat content was highest in the hepatic steatosis (median 15.4 %, IQR 10.0-19.3) and glycogenic hepatopathy (median 6.5 %, IQR 4.5-9.1) groups and compared to both of these groups was lower in the control group (median 1.0 %, IQR 0.7-1.1, p 0.002 and 0.022), the T1DM group with satisfactory control (median 0.3 %, IQR 0.2-0.6, p < 0.001 and <0.001), and the T1DM group with poor control without liver disease (median 1.1 %, IQR 0.9-1.1, p 0.001 and 0.012). No participants from the type 1 diabetes poor control, type 1 diabetes satisfactory control or the no diabetes groups had 1 H-MRS-diagnosed hepatic steatosis. 1 H-MRS glycogen content could not be interpreted in the majority of those with glycogenic hepatopathy because of interference from the fat signal.
Conclusions: In cases diagnosed with glycogenic hepatopathy there may be significant concomitant fat accumulation, compounding the already elevated cardiovascular risk in this cohort. The technique of 1 H-MRS has not been demonstrated to be useful for diagnosing glycogenic hepatopathy.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: